Idt Australia Limited · ASX:IDT
Idt Australia — Investor Presentation (August 2013)
10 slides from Idt Australia's investor presentation, Aug 16, 2013
Slide 1: Company Presentation August 2013
8/16/2013 For personal use only Company Presentation August 2013 Disclaimer The purpose of the presentation is to provide an update of the business of IDT Australia Ltd (ASX:IDT). These slides have been prepared as a presentation aid only and the information they contain may require further explanat
Slide 2: IDT Australia Ltd (ASX.AX)
8/16/2013 IDT Australia Ltd (ASX.AX) For personal use only • Established in 1975 as a contract drug development company • Listed on the ASX in 1988 (IDT.AX) • CMAX acquired 2002 • Has participated in the CMC and/or clinical development of over 60 marketed drugs • 9 US and 5 Japanese Drug Master File
Slide 3: Carried Value: Drug Master Files and GMP Development
8/16/2013 Carried Value: Drug Master Files and GMP Development For personal use only Japan DMFs USA DMFs Other APIs Finished Dose Mitoxantrone Mitoxantrone Fentanyl Temozolomide Acetazolamide Acetazolamide PentosanPS Na Conj. Estrogens Thiotepa Temsirolimus Thalidomide Hematoporphyrin Hematoporphyri
Slide 4: Reference Clients; Approvals and Certifications
8/16/2013 Reference Clients For personal use only Manufacturing Clinical Approvals and Certifications • US FDA Certified, API and finished products • Japanese Dept. Health Labour & Welfare Certified, non-sterile drugs • Australian TGA Licensed, API and finished products – Reciprocal EU recognition 4
Slide 5: Melbourne Manufacturing Campus
8/16/2013 Melbourne Manufacturing Campus 12,000m2 freehold site For personal use only $70m+ replacement value, $10m unimproved land value 1. Engineering 2. Warehouses/ 10 inward goods 10 3. Cytotoxic labs 4. Dev. labs 5. Administration 1 6. Controlled store 2 7. Antibiotic API/FP 1 8. HPAPI + steril
Slide 6: CMAX Facilities
8/16/2013 CMAX Facilities For personal use only • Australia’s largest Clinical Trials Unit • Totally confined 50 bed residential facility • Outpatient treatment/monitoring room • Fully integrated into hospital emergency response services • 24-bed ambulatory 12 lead cardiac telemetry system • Sample
Slide 7: Clinical Experience: studies over years
8/16/2013 Clinical Experience: 425 studies over 17 years For personal use only Dermatology (psoriasis, atopic 1% 1% dermatitis) 3% Respiratory (COPD, asthma) 5% Oncology 10% 30% Endocrine (diabetes, obesity) Neurology/Pain 10% Rheumatology Hepatology/ID 10% Haematology 20% Renal 10% Ophthalmology Au
Slide 8: New Management Team: Driving Growth and Value
8/16/2013 New Management Team: Driving Growth and Value For personal use only A. Organic business growth and a return to profitability through better sales and marketing, and efficiencies B. Previously underleveraged off balance sheet assets: DMFs and generic oncology registrations C. Transformation
Slide 9: Corporate Snapshot (as at 15Aug13)
8/16/2013 Corporate Snapshot (as at 15Aug13) For personal use only Financials 2012 2013* 1 year trading history Rev $9.9m $10.6m EBIT ($3.6) ($4.4) Cash ($1.4) ($2.2) Debt $1.95m NTAB/share $0.57 (weighted) *unaudited 5 year trading history Register • 53.4m shares on issue • 500,000 options (unliste
Slide 10: Paul D. R. MacLeman, Chief Executive Officer
8/16/2013 For personal use only Paul D. R. MacLeman Chief Executive Officer +61 3 9801-8888 info@idtaus.com.au 10